Ultra Low Dose Orbital Radiation Therapy in Treating Patients With Stage I-IV Indolent B-cell Lymphoma or Mantle Cell Lymphoma

Sponsor

M.D. Anderson Cancer Center (Other)

Overall Status

Active, not recruiting

CT.gov ID

NCT02494700

Collaborator

National Cancer Institute (NCI) (NIH)

Enrollment

Location

Arm

107.5

Anticipated Duration (Months)

0.5

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This phase II trial studies how well ultra low dose orbital radiation therapy works in treating patients with stage I-IV low grade (indolent) B-cell lymphoma or mantle cell lymphoma involving the orbit of the eye (space enclosed by the borders of the eye socket). Orbital radiation therapy uses external beam radiation to destroy cancer cells. Using ultra low dose orbital radiation therapy may be effective in treating indolent B-cell lymphoma or mantle cell lymphoma involving the eye and may have fewer side effects.

Condition or Disease	Intervention/Treatment	Phase
Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma Ann Arbor Stage I Grade 1 Follicular Lymphoma Ann Arbor Stage I Grade 2 Follicular Lymphoma Ann Arbor Stage I Indolent Adult Non-Hodgkin Lymphoma Ann Arbor Stage I Mantle Cell Lymphoma Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma Ann Arbor Stage II Grade 1 Follicular Lymphoma Ann Arbor Stage II Grade 2 Follicular Lymphoma Ann Arbor Stage II Indolent Adult Non-Hodgkin Lymphoma Ann Arbor Stage II Mantle Cell Lymphoma Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma Ann Arbor Stage III Grade 1 Follicular Lymphoma Ann Arbor Stage III Grade 2 Follicular Lymphoma Ann Arbor Stage III Indolent Adult Non-Hodgkin Lymphoma Ann Arbor Stage III Mantle Cell Lymphoma Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma Ann Arbor Stage IV Grade 1 Follicular Lymphoma Ann Arbor Stage IV Grade 2 Follicular Lymphoma Ann Arbor Stage IV Indolent Adult Non-Hodgkin Lymphoma Ann Arbor Stage IV Mantle Cell Lymphoma Ocular Adnexal Lymphoma Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma Orbit Lymphoma	Radiation: External Beam Radiation Therapy Drug: Orbital Radiation	Phase 2

Detailed Description

PRIMARY OBJECTIVES:

To evaluate the efficacy of ultra low dose 4 Gray (Gy) orbital radiation, measured as local orbital control (i.e. local control within the radiation field), in patients with limited and advanced stage low grade B lymphocyte (B cell) lymphoma and mantle cell lymphoma involving the ocular adnexa.
To evaluate the efficacy of ultra low dose 4 Gy orbital radiation, measured as complete response, in patients with limited and advanced stage low grade B cell lymphoma and mantle cell lymphoma involving the ocular adnexa.
To evaluate the acute and chronic toxicity of radiation to the orbit.

SECONDARY OBJECTIVE:

To determine if dynamic contrast enhanced magnetic resonance imaging can predict response to ultra low dose radiation therapy.

OUTLINE:

Patients undergo low dose orbital external beam radiation therapy (EBRT) on 2 consecutive days. Patients experiencing stable or progressive disease after 12-16 weeks of EBRT undergo additional low dose orbital EBRT over 10 fractions. Patients experiencing partial response or minimal response 1 year after EBRT also undergo low dose orbital EBRT over 10 fractions.

After completion of study treatment, patients are followed up every 3-4 months for 6-8 months, every 6-12 months for up to 2 years, and then periodically thereafter.

Study Design

Study Type:

Interventional

Actual Enrollment :

50 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Ultra Low Dose 4 Gy Orbital Radiation for Definitive Therapy of Indolent B Cell Lymphoma

Actual Study Start Date :

Jul 6, 2015

Anticipated Primary Completion Date :

Jun 20, 2023

Anticipated Study Completion Date :

Jun 20, 2024

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Treatment (low dose orbital EBRT) Patients undergo two fractions of low dose orbital EBRT on 2 consecutive days. Patients experiencing stable or progressive disease after 12-16 weeks of EBRT undergo additional low dose orbital EBRT over 10 fractions. Patients experiencing partial response or minimal response 1 year after EBRT also undergo low dose orbital EBRT over 10 fractions.	Radiation: External Beam Radiation Therapy Undergo orbital EBRT Other Names: Definitive Radiation Therapy EBRT External Beam Radiotherapy External Beam RT external radiation External Radiation Therapy external-beam radiation Drug: Orbital Radiation Participants receive radiation to entire involved orbit for a total dose of 4 Gy in 2 fractions over two consecutive days with external beam radiotherapy. If there is stable disease or progressive disease, an additional 20 Gy administered to involved site. If there are two consecutive evaluations with no change in disease burden then an additional 20 Gy administered. At one year if there is persistent disease, an additional 20 Gy administered to involved site. Other Names: XRT

Arm

Intervention/Treatment

Experimental: Treatment (low dose orbital EBRT)

Patients undergo two fractions of low dose orbital EBRT on 2 consecutive days. Patients experiencing stable or progressive disease after 12-16 weeks of EBRT undergo additional low dose orbital EBRT over 10 fractions. Patients experiencing partial response or minimal response 1 year after EBRT also undergo low dose orbital EBRT over 10 fractions.

Radiation: External Beam Radiation Therapy

Undergo orbital EBRT

Other Names:

Definitive Radiation Therapy

EBRT

External Beam Radiotherapy

External Beam RT

external radiation

External Radiation Therapy

external-beam radiation

Drug: Orbital Radiation

Participants receive radiation to entire involved orbit for a total dose of 4 Gy in 2 fractions over two consecutive days with external beam radiotherapy. If there is stable disease or progressive disease, an additional 20 Gy administered to involved site. If there are two consecutive evaluations with no change in disease burden then an additional 20 Gy administered. At one year if there is persistent disease, an additional 20 Gy administered to involved site.

Other Names:

XRT

Outcome Measures

Primary Outcome Measures

Local orbital control (i.e. local control within the radiation field) [Up to 2 years post-radiation]
Local orbital event will be estimated using the Kaplan-Meier method.

Secondary Outcome Measures

Complete response rate [Up to 2 years]
Response rate will be estimated along with 95% confidence intervals.
Local regional control (i.e. local control within the ipsilateral orbit but outside of the radiation field) [Up to 2 years post-radiation therapy]
Overall survival (OS) [Up to 2 years]
OS will be estimated using the Kaplan-Meier method.
Freedom from distant relapse rates [Up to 2 years]
Incidence of acute and chronic ocular toxicities graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03 [Up to 2 years]
Toxicity data will be summarized by frequency tables.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Patients with stage I-IV indolent B cell lymphoma, including mucosa-associated lymphoid tissue (MALT) and follicular grade I/II; patients with mantle cell lymphoma will also be included in this study, as mantle cell lymphoma is also radiosensitive, despite it not being an indolent B cell lymphoma; patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) are ineligible
Patients must have measurable disease within the orbit, either clinically and/or radiographically after biopsy confirmation of B cell lymphoma
Bilateral ocular adnexal involvement is permitted, if biopsy confirms unilateral disease and there is high clinical suspicion for bilateral disease, biopsy of the contralateral ocular adnexa can be waived
Female patients of childbearing potential must have a negative serum pregnancy test (beta-human chorionic gonadotropin [hCG]) within 2 weeks of protocol entry
Planned systemic therapy after orbital radiation therapy is permitted however the timing of systemic therapy will be recorded and patients will be stratified according to receipt of adjuvant systemic therapy
Male patients must agree to use a barrier method of contraception or agree to abstain from heterosexual activity for the duration of the study
Female patients must be willing to use two adequate barrier methods of contraception to prevent pregnancy or agree to abstain from heterosexual activity throughout the study or be post-menopausal (free from menses > two years or surgically sterilized)
Patients must have the ability to give informed consent

Exclusion Criteria:

Patients treated with chemotherapy for lymphoma within 4 weeks of protocol enrollment (including Rituxan)
Patients with aggressive B cell lymphoma histology, including diffuse large B cell lymphoma (DLBCL) and grade 3 follicular lymphoma
Patients with chronic lymphocytic leukemia/small lymphocytic lymphoma
Patients with a history of prior radiation to the orbit if re-treatment would exceed known orbital tolerance
Patients with pre-existing retinopathy
Patients who are pregnant
Patients with active lupus or scleroderma are ineligible